Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZL-012 for Submental Fat Reduction
NCT04086823Phase 2Completed
- Sponsor
- Raziel Therapeutics
- Start
- Feb 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in submental fat comparing RZL-012 with Vehicle (2 arms). Primary endpoint: Adverse Events Follow up. Started Feb 2020; status: completed.
02
Drugs
Tapencarium
03
Conditions
submental fat
Beyond the preview
Go deeper on NCT04086823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086823.